or Try an Advanced Search...

    Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    D 11.31 -3.50% -0.41
    IOVA closed down 3.5 percent on Friday, April 19, 2024, on 52 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 7
    *** please verify all earnings dates ***
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical IOVA trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish -3.50%
    Doji - Bullish? Reversal -3.50%
    Wide Bands Range Expansion -3.50%
    Oversold Stochastic Weakness -3.50%
    Lower Bollinger Band Walk Weakness -4.15%
    Inside Day Range Contraction -4.15%
    Older End-of-Day Signals for IOVA ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Lower Bollinger Band about 14 hours ago
    Lower Bollinger Band Support about 16 hours ago
    Down 5% about 17 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 3% about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IOVA Chart by TradingView
    Basic chart:

    Profile

    Iovance Biotherapeutics, Inc. Description

    Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Oncology Cancer Immunotherapy Cell Therapy Melanoma Antineoplastic Drugs Cancer Cell Lymphocytes Checkpoint Inhibitor Adoptive Cell Transfer Head And Neck Cancer Immunotherapy Products National Cancer Institute Cancer Immunotherapy Product Metastatic Melanoma Pembrolizumab Tumor Infiltrating Lymphocytes Breast And Lung Cancer Ocular Melanoma

    Is IOVA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 9 Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
    Apr 9 Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
    Apr 8 Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
    Apr 5 Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
    Mar 29 Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
    Mar 26 2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
    Mar 25 Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
    Mar 23 U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies
    Mar 19 Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week
    Mar 19 7 Biotech Stocks Ready to Ride the Sector’s Resurgence
    See more IOVA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.33
    52 Week Low 3.21
    Average Volume 10,062,117
    200-Day Moving Average 8.14
    50-Day Moving Average 13.76
    20-Day Moving Average 13.23
    10-Day Moving Average 12.31
    Average True Range 0.83
    RSI (14) 33.33
    ADX 18.99
    +DI 14.42
    -DI 29.04
    Chandelier Exit (Long, 3 ATRs) 13.41
    Chandelier Exit (Short, 3 ATRs) 13.50
    Upper Bollinger Bands 15.41
    Lower Bollinger Band 11.06
    Percent B (%b) 0.06
    BandWidth 32.85
    MACD Line -0.64
    MACD Signal Line -0.38
    MACD Histogram -0.2613
    Fundamentals Value
    Market Cap 2.89 Billion
    Num Shares 256 Million
    EPS -2.08
    Price-to-Earnings (P/E) Ratio -5.44
    Price-to-Sales 3590.82
    Price-to-Book 3.49
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.33
    Resistance 3 (R3) 12.34 12.02 12.16
    Resistance 2 (R2) 12.02 11.76 12.01 12.10
    Resistance 1 (R1) 11.66 11.60 11.50 11.65 12.05
    Pivot Point 11.34 11.34 11.26 11.33 11.34
    Support 1 (S1) 10.98 11.08 10.82 10.97 10.57
    Support 2 (S2) 10.66 10.92 10.65 10.52
    Support 3 (S3) 10.30 10.66 10.46
    Support 4 (S4) 10.29